GenScript Biotech Corporation Overview - GenScript Biotech Corporation aims to be a leading global CDMO, known for cutting-edge technology, and a creator of solutions for a better life through bio-innovation[6] - The company's growth framework is built on innovation in DNA synthesis & design, protein design & engineering, and cell design & engineering[7] - The group's cash position is $966.6 million[11] - GenScript has a global presence, serving over 100 countries and regions with 200,000+ customers[14] Business Strategy and Financial Goals - By 2035, GenScript aims for $3 billion in revenue with over 20% operating margin, $3 billion accumulated licensing revenue, 50% revenue from products, and over 80% revenue from high-margin markets[20, 46] - The company is focusing on high-quality growth with better profitability[20] - GenScript is leveraging core technology advantages to accelerate products and high-value licensing, building a new growth engine with AI and digital engine[20] GenScript Life Science Group (LSG) - GenScript LSG has over 239,500 customers and 3,300+ employees, with 10% in R&D[59] - Accumulated citations of GenScript services & products in customer research publications exceed 112,200[65] - TurboCHOTM can produce antibodies from sequence in 5 days[98] ProBio (Biologics CRDMO) - ProBio aims to be a leading global CDMO, enabling customers to deliver life-changing therapies[6, 127] - The company has $371.1 million in cash position[137] - The biologics CDMO market is projected to be a $16 billion market with a 12% CAGR, while the CGT CDMO market is at $5.6 billion[166] - In vivo CAR-T trial starts grew 220% from 2024 to 2025[166] Bestzyme (Industrial Synthetic Biology) - Bestzyme's vision is to be the creator of solutions for a better life, powered by leading bio-innovation[6, 224] - The company has over 40% of staff in R&D, 60+ granted patents, and 130+ patent applications[233] - Bestzyme has a 23% revenue CAGR and 22% gross profit CAGR in 2022-2024[233]

Core Concept - Glocalization tailors global products to local markets [1] - Companies use glocalization to enhance competitiveness [1] - Glocalization helps meet regional consumer needs [1]

Core Viewpoint - The Company is proposing a secondary listing of its ordinary shares on the Singapore Exchange, which aims to attract funds focused on Asia-Pacific investments and enhance its business development in Southeast Asia and the Middle East [1][3]. Group 1: Proposed Secondary Listing - The Company has submitted a confidential application for the proposed secondary listing on the SGX-ST and is awaiting the eligibility-to-list letter from the SGX-ST [2][5]. - The proposed secondary listing will not involve the issuance of new shares, and the shares will continue to be primarily listed on the Hong Kong Stock Exchange [1]. Group 2: Business Development and Strategy - The Company aims to optimize its shareholder structure and enhance its global reputation and market position through the proposed secondary listing [3]. - Singapore has been established as the regional headquarters for the Company's Southeast Asia and Middle East business, covering the entire pharmaceutical value chain [3]. - The Company operates several subsidiaries in Singapore, including CMS R&D, PharmaGend, Rxilient, and Singapore Venture Capital, to provide high-quality treatment options and contribute to the pharmaceutical industry in Southeast Asia [3]. Group 3: Market Position and Focus - The Company focuses on global first-in-class (FIC) and best-in-class (BIC) innovative products, promoting clinical research and commercialization to benefit patients [7]. - The Company has developed proven commercialization capabilities and extensive networks in specialty therapeutic fields, aiming to strengthen its market position in cardio-cerebrovascular, gastroenterology, skin health, and ophthalmology businesses [8]. - The Company is striving to become a "bridgehead" for global pharmaceutical companies entering the Southeast Asian market, supporting sustainable development [8].